Cetuximab in Neoadjuvant Treatment of Non-Resectable Colorectal Liver Metastases (CELIM)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT00153998 |
|
Recruitment Status :
Completed
First Posted : September 12, 2005
Last Update Posted : February 27, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
General Objectives:
- To test the feasibility of neoadjuvant treatment with cetuximab/chemotherapy followed by liver resection
- To determine the optimal combination (cetuximab/FOLFOX versus cetuximab/FOLFIRI) for further trials in preoperative chemotherapy
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Colorectal Cancer Liver Metastases | Drug: Cetuximab Procedure: Liver resection Drug: Cetuximab and FOLFIRI Drug: Cetuximab and FOLFOX | Phase 2 |
Patients with liver metastasis will be screened for this study. Eligible patients will complete the pretreatment evaluation including an abdominal CT scan that will be presented to the local surgeon and the radiologist for proving of resectability of hepatic lesions. Additionally, CT scans will be reviewed by three reference surgeons. In case of non-resectability, as defined above, CT- or ultrasound- guided biopsy of one of the liver metastases will be performed, unless biopsy material is available from prior biopsy of one of the liver metastases.
Instead of an ultrasound-guided biopsy, a CT-guided biopsy may be performed.
Formalin-fixed, paraffin embedded metastatic tissue will be sent to reference laboratory (Prof. Störkel, Wuppertal) for immunohistochemical analysis of EGFR- expression.
Additionally tissue will be stored in "RNA later" for gene expression analysis if agreed by the patient.
Additionally, the primary tumor will be collected and sent to the reference laboratory for analysis of EGFR- expression (if agreement of the patient exists).
Patients will be randomized to a combination of:
Cetuximab/FOLFIRI (irinotecan/5-FU/FA) or Cetuximab/FOLFOX6 (oxaliplatin/5-FU/FA)
All patients receive a four month treatment (eight cycles) of the allocated treatment.
Resection is planned after completion of neoadjuvant treatment and should be performed between 4 and 6 weeks after the last dose of chemotherapy. Probes of the resected material (in liquid nitrogen and paraffin embedded material will be collected).
If a resection is not possible after eight administrations of chemotherapy, chemotherapy will be continued until tumor progression (maximal duration of treatment 2 years) and the patient will be evaluated for a potential resection every two months.
After resection, postoperative treatment is planned for 3 months (6 cycles). Treatment start is planned between 4 and 8 weeks after the operation.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 135 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Open, Randomized, Multicenter, Randomized Phase II Trial Comparing the Combination of Cetuximab With Oxaliplatin/5-FU/FA Versus the Combination of Cetuximab With Irinotecan/5-FU/FA as Neoadjuvant Treatment in Patients With Non-Resectable Colorectal Liver Metastases |
| Study Start Date : | November 2004 |
| Actual Primary Completion Date : | March 2008 |
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: 1
Cetuximab and FOLFIRI
|
Drug: Cetuximab Procedure: Liver resection Drug: Cetuximab and FOLFIRI Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by: Cetuximab 250 mg/m² (1.0 h i.v.) weekly Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.) Other Names:
|
|
Active Comparator: 2
Cetuximab and FOLFOX
|
Drug: Cetuximab Procedure: Liver resection Drug: Cetuximab and FOLFOX Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by: Cetuximab 250 mg/m² (1.0 h i.v.) weekly Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.) Other Names:
|
- Tumor response, defined as partial and complete response according to RECIST (Response Evaluation Criteria in Solid Tumors) - criteria in the intention-to-treat [ITT-] population
- Rate of R0 liver resection (ITT- population)
- Progression free survival (ITT- population)
- Disease free survival after resection (ITT- population)
- Overall survival (ITT- population)
- Safety (all patients that received any study drug)
- Molecular predictive markers for response and toxicity
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Patients with non-resectable, histologically confirmed, synchronous or metachronous colorectal liver metastases. Patients with non-resectable metastases are defined as; patients with five or more liver metastases; and/or patients with liver metastases that are technically non-resectable (local surgeon in cooperation with local radiologist will define non-resectability on the basis of remaining functional liver tissue, infiltration of all liver veins, infiltration of both liver arteries, both portal branches or both bile ducts).
- Patients with simultaneous liver metastases are eligible, if the primary tumor has been resected at least 1 month prior to chemotherapy.
- Karnofsky Performance Status ≥ 80
- Informed consent
- Adequate bone marrow function, liver and renal function (neutrophils > 1.5 x 10^9/l; thrombocytes > 100 x 10^9/l; hemoglobin > 8.0 g/l; bilirubin ≤ 1.5 x upper limit of normal [ULN] and not increasing more than 25% within the last 4 weeks; ALAT and ASAT < 5 x UNL; serum creatinine ≤ 1.5 x UNL)
- Age ≥ 18 years
Exclusion Criteria:
- Any evidence of extrahepatic metastases, lymph node metastases and primary tumor recurrence
- Prior chemotherapy (except adjuvant chemotherapy with an interval of ≥ 6 months)
- Previous exposure to EGFR (epidermal growth factor receptor)-targeting therapy
- Radiotherapy or major abdominal or thoracic surgery (excluding diagnostic biopsy or port implantation) ≤ 4 weeks before study entry
- Concurrent systemic immune therapy, chemotherapy, or hormone therapy
- Investigational agents or participation in clinical trials within 30 days before start of the treatment in study
- Clinically relevant coronary disease or myocardial infarction within 12 months before study entry
- Peripheral neuropathy > CTC grade I
- Inflammatory bowel disease
- Previous malignancy (except colorectal cancer, history of basal cell carcinoma of skin or pre-invasive carcinoma of the cervix with adequate treatment)
- History of severe psychiatric illness
- Drug or alcohol abuse
- Breast feeding or pregnant women, no effective contraception if risk of conception exists (male and female patients)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00153998
Show 21 study locations
| Principal Investigator: | Claus-Henning Köhne, Prof. Dr. | Klinikum Oldenburg GmbH, Dr.-Eden-Str.10; 26133 Oldenburg | |
| Principal Investigator: | Gunnar Folprecht, Dr. | University Hospital Dresden, Fetscherstr. 74, 01307 Dresden, Germany |
| Responsible Party: | Prof. Dr. Claus-Henning Köhne, now: Klinikum Oldenburg gGmbH |
| ClinicalTrials.gov Identifier: | NCT00153998 |
| Other Study ID Numbers: |
CELIM |
| First Posted: | September 12, 2005 Key Record Dates |
| Last Update Posted: | February 27, 2009 |
| Last Verified: | April 2007 |
|
Cetuximab Oxaliplatin Irinotecan 5-FU |
Chemotherapy Resection Liver resection Neoadjuvant |
|
Neoplasm Metastasis Liver Neoplasms Digestive System Neoplasms Neoplasms by Site Neoplasms Digestive System Diseases Neoplastic Processes Pathologic Processes Liver Diseases Leucovorin Folic Acid Fluorouracil Oxaliplatin Irinotecan Cetuximab |
Levoleucovorin Antimetabolites Molecular Mechanisms of Pharmacological Action Antimetabolites, Antineoplastic Antineoplastic Agents Immunosuppressive Agents Immunologic Factors Physiological Effects of Drugs Topoisomerase I Inhibitors Topoisomerase Inhibitors Enzyme Inhibitors Antidotes Protective Agents Vitamin B Complex Vitamins |